A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer
Authors
Keywords
Metastatic colorectal cancer,Refractory disease, TAS-102, Trametinib
Journal
Clinical Colorectal Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-24
DOI
10.1016/j.clcc.2022.05.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
- (2021) Josep Tabernero et al. Future Oncology
- RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
- (2021) Stefan Kasper et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
- (2020) Per Pfeiffer et al. LANCET ONCOLOGY
- A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
- (2019) Michael Cecchini et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
- (2019) Jai-Hee Moon et al. BRITISH JOURNAL OF CANCER
- MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer
- (2019) Tianzuo Zhan et al. Nature Communications
- Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
- (2019) Tsubaki et al. Cancers
- A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy
- (2017) May Cho et al. Oncotarget
- MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism
- (2016) Diane M. Pereira et al. Oncotarget
- Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases
- (2015) Yuan Yan et al. ANTI-CANCER DRUGS
- Metastatic Colorectal Cancer: Current State and Future Directions
- (2015) Marwan G. Fakih JOURNAL OF CLINICAL ONCOLOGY
- Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer
- (2015) M. Raja et al. MOLECULAR CANCER THERAPEUTICS
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells
- (2013) Motoki Watanabe et al. CANCER SCIENCE
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005
- (2011) Lee Cheng et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
- (2011) M. E. Urick et al. CLINICAL CANCER RESEARCH
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started